In the preceding three months, 18 analysts have released ratings for Apellis Pharmaceuticals APLS, presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 4 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 4 | 1 | 1 | 0 | 0 |
| 3M Ago | 4 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $75.94, a high estimate of $106.00, and a low estimate of $54.00. This upward trend is apparent, with the current average reflecting a 12.6% increase from the previous average price target of $67.44.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Apellis Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $92.00 | - |
| Laura Chico | Wedbush | Raises | Neutral | $67.00 | $60.00 |
| Graig Suvannavejh | Mizuho | Raises | Neutral | $60.00 | $49.00 |
| Colleen Kusy | Baird | Maintains | Outperform | $81.00 | - |
| Akash Tewari | Jefferies | Raises | Buy | $80.00 | $68.00 |
| Justin Kim | Oppenheimer | Raises | Outperform | $79.00 | $75.00 |
| Joseph Stringer | Needham | Raises | Buy | $75.00 | $70.00 |
| Colleen Kusy | Baird | Raises | Outperform | $81.00 | $71.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $92.00 | $82.00 |
| Laura Chico | Wedbush | Raises | Neutral | $60.00 | $39.00 |
| Steven Seedhouse | Raymond James | Raises | Strong Buy | $106.00 | $67.00 |
| Salveen Richter | Goldman Sachs | Raises | Buy | $90.00 | $65.00 |
| Yigal Nochomovitz | Citigroup | Lowers | Buy | $67.00 | $70.00 |
| Justin Kim | Oppenheimer | Lowers | Outperform | $75.00 | $88.00 |
| Steven Seedhouse | Raymond James | Lowers | Strong Buy | $67.00 | $93.00 |
| Joseph Stringer | Needham | Lowers | Buy | $56.00 | $63.00 |
| Derek Archila | Wells Fargo | Lowers | Equal-Weight | $54.00 | $67.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $85.00 | $52.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Apellis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Apellis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Apellis Pharmaceuticals analyst ratings.
Discovering Apellis Pharmaceuticals: A Closer Look
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
Financial Milestones: Apellis Pharmaceuticals's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 400.54% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -127.03%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -48.55%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.18%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
